Fitness & Nutrition News

Welcome to AI Decoded, Fast Company’s weekly newsletter that breaks down the most important news in the world of AI. You can sign up to receive this newsletter every week via email here.

We often feel that we are "on the same wavelength" with one another, but can science identify and engineer this phenomenon? Studies by a team of neuroscience researchers suggest that it's possible—a connectivity that is both beneficial and can be enhanced for therapeutic and other purposes.

The Atherogenic Index of Plasma (AIP) is a marker of atherosclerosis, and the Frailty Index (FI) reflects physiological decline. The combined effect of AIP and FI remains insufficiently studied. This study aimed to investigate the association between a combined AIP-FI measure and the risk of arthritis. This study utilized data from the China Health and Retirement Longitudinal Study (CHARLS) database between 2011 and 2020. A total of 4437 participants aged ≥ 45 years without arthritis at baseline were included. Cox proportional hazards regression models and restricted cubic spline (RCS) models were employed to explore the relationship between the AIP-FI and the risk of incident arthritis. Over a 10-year follow-up period, a total of 1470 participants developed arthritis, with an incidence rate of 33.13%. Cox regression analysis revealed that each 1-unit increase in AIP-FI was associated with a 3% increase in arthritis risk (HR = 1.03; 95% CI: 1.02 to 1.04). Participants in the highest tertile (T3) of AIP-FI had a 55% higher risk compared to those in the lowest tertile (T1) (HR = 1.55; 95% CI: 1.35 to 1.78). The RCS curve demonstrated a significant nonlinear positive association between AIP-FI and arthritis risk (P for overall < 0.001, P for nonlinear < 0.001). This study indicates that a higher AIP-FI is significantly associated with an increased risk of arthritis. By integrating metabolic and frailty data, the AIP-FI was associated with arthritis risk and may help identify older Chinese adults at higher risk. However, these findings require further validation in independent cohorts before any clinical consideration.

NANJING, China, June 26, 2026 /PRNewswire/ -- Recently, the NDA for Sumecigrel Capsule (formerly known as Vicagrel), a Class 1 innovative antiplatelet drug developed by Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech), has been officially accepted by the NMPA. The drug has now entered the NDA stage. As a global pioneer in novel antiplatelet agents, Sumecigrel is expected to provide a new and improved treatment option to tens of millions of patients with cardiovascular and cerebrovascular diseases.

NASA has delivered the first braking engines for ESA’s Rosalind Franklin Mars mission. Work to secure the required RHUs continues.

In an analysis reported in the Journal of Clinical Oncology, Wilson et al found that prophylactic high-dose methotrexate does not provide significant benefit in reducing central nervous system (CNS) r...

Harvard economist Rebecca Diamond found weight loss on GLP-1 drugs like Ozempic improved women's prospects of getting hired or meeting a partner.

Researchers at National Jewish Health have uncovered a previously unknown mechanism that helps drive inflammation in allergic asthma, offering new insight into how the disease develops and potentially revealing new targets for future therapies.

Uganda's Ministry of Health warns male survivors of Ebola, warning that while they may have recovered from the disease, the virus can remain in semen

Before joints become painful, psoriatic arthritis (PsA) often begins silently as enthesitis—inflammation where tendons and ligaments attach to bone.